GlassScriptPhysician profile
Brooke Dunlavy
NPI 1730440603
$6,179.16
in general payments reported to CMS, 2019-2025
58 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $571 · 2021: $968 · 2022: $786 · 2023: $819 · 2024: $301 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $510 · Education: $38.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $510.00 |
| Education | $38.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,774.19 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $511.75 | 2019-2025 | |
| Novo Nordisk INC | $434.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $428.16 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $348.98 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Allergan, INC. | $328.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $327.12 | 2024-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $190.98 | 2019-2025 | Veozah |
| Currax Pharmaceuticals LLC | $131.00 | 2023 | Contrave, Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.89 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $121.40 | 2019-2024 | Gardasil, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $113.23 | 2022 | |
| Daiichi Sankyo INC. | $90.46 | 2020-2022 | |
| Lundbeck LLC | $86.66 | 2025 | Rexulti |
| Exact Sciences Corporation | $75.53 | 2023-2025 | Cologuard Collection Kit |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Dunlavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.